475858 Met30 Antagonist, SMER3 - Calbiochem

475858
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Empirical Formula
      C₁₁H₄N₄O₂

      Prix & Disponibilité

      Référence DisponibilitéConditionnement Qté Prix Quantité
      475858-25MG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Flacon en verre 25 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewA cell-permeable indenofurazinopyrazinone compound that is shown to directly target the F-box protein Met30 subunit of the Skp1-cullin-F-box (SCF) E3 ubiquitin ligase complex, disrupting Met30-Skp1 interaction and selectively inhibiting SCFMet30, but not SCFCdc4, E3 ubiquitin ligase activity. SMER3 is reported to act in a synthetic lethal fashion with rapamycin (Cat. Nos. 553210, 553211, & 553212) in both human lung cancer A549 and in yeast cultures. SMER3 treatment (10 to 30 µM) results in cell cycle arrest and morphological phenotype resembling that seen with temperature-sensitive Met30, but not Skp1 or Cdc4, mutant under non-permissive temperature in yeast cultures.
          Catalogue Number475858
          Brand Family Calbiochem®
          SynonymsSmall-Molecule Enhancer of Rapamycin-3, 9H-Indeno[1,2-b][1,2,5]oxadiazolo[3,4-e]pyrazin-9-one, Indeno[1,2-b]furazano[3,4-E]pyrazin-9-one, SCFMet30 Inhibitor
          References
          ReferencesAghajan, M., et al. 2010. Nature Biotechnol. 28, 738.
          Product Information
          FormYellow solid
          Hill FormulaC₁₁H₄N₄O₂
          Chemical formulaC₁₁H₄N₄O₂
          Structure formula ImageStructure formula Image
          Quality LevelMQ100
          Applications
          Biological Information
          Purity≥97% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Regulatory Review
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Met30 Antagonist, SMER3 - Calbiochem FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          Met30 Antagonist, SMER3 - Calbiochem Certificats d'analyse

          TitreNuméro de lot
          475858

          Références bibliographiques

          Aperçu de la référence bibliographique
          Aghajan, M., et al. 2010. Nature Biotechnol. 28, 738.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision24-October-2011 RFH
          SynonymsSmall-Molecule Enhancer of Rapamycin-3, 9H-Indeno[1,2-b][1,2,5]oxadiazolo[3,4-e]pyrazin-9-one, Indeno[1,2-b]furazano[3,4-E]pyrazin-9-one, SCFMet30 Inhibitor
          DescriptionA cell-permeable indenofurazinopyrazinone compound that is shown to directly target the F-box protein Met30 subunit of the Skp1-cullin-F-box (SCF) E3 ubiquitin ligase complex, disrupting Met30-Skp1 interaction and selectively inhibiting SCFMet30, but not SCFCdc4, E3 ubiquitin ligase activity. SMER3 is reported to act in a synthetic lethal fashion with rapamycin (Cat. Nos. 553210, 553211, & 553212) in both human lung cancer A549 and in yeast cultures. SMER3 treatment (10 to 30 µM) results in cell cycle arrest and morphological phenotype resembling that seen with temperature-sensitive Met30, but not Skp1 or Cdc4, mutant under non-permissive temperature in yeast cultures.
          FormYellow solid
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₁₁H₄N₄O₂
          Structure formulaStructure formula
          Purity≥97% by HPLC
          SolubilityDMSO (10 mg/ml). It is recommended to prepare a stock solution for 3 month use each time and store the unreconstituted material in solid form, protected from moisture and preferably under inert gas, for best long-term stability during storage.
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Regulatory Review
          ReferencesAghajan, M., et al. 2010. Nature Biotechnol. 28, 738.